tm logo
SURMOUNT BIO
Live/Pending
FIRST EXTENSION - GRANTED

granted

on 07 Jun 2024

Last Applicant/ Owned by

139 Main Street, Suite 500

Cambridge

MA

02142

Serial Number

97690153 filed on 23rd Nov 2022

Registration Number

N/A

Correspondent Address

Maury M. Tepper, III TEPPER & EYSTER, PLLC

3724 BENSON DRIVE

RALEIGH, NC 27609

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

SURMOUNT BIO

"BIO" Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiop Read More

Classification Information


Class [005]
Pharmaceutical Products


Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Biological preparations for the treatment of cancer; Digestives for pharmaceutical purposes; Drug delivery agents in the form of a capsule, pill, or liquid that facilitate the delivery of pharmaceutical preparations; Medical preparations for the treatment of cancer, cystic fibrosis, heart disease, and AIDS; Medicinal infusions for treating Cancer, cystic fibrosis, heart disease, and AIDS; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations for the treatment and prevention of Cancer, cystic fibrosis, heart disease, and AIDS; Pharmaceutical products for the prevention and treatment of cancer; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Therapeutic pharmaceutical for the treatment of Cancer, cystic fibrosis, heart disease, and AIDS; Unit dose capsules sold empty for pharmaceutical use


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 97690153

Mark Type

No Service/Collective Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
13th Jun 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07th Jun 2024SOU EXTENSION 1 GRANTED
07th Jun 2024SOU EXTENSION 1 FILED
07th Jun 2024SOU TEAS EXTENSION RECEIVED
12th Dec 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
17th Oct 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17th Oct 2023PUBLISHED FOR OPPOSITION
27th Sep 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11th Sep 2023APPROVED FOR PUB - PRINCIPAL REGISTER
11th Sep 2023EXAMINER'S AMENDMENT ENTERED